| Study Investigating Novoeight®/NovoEight® (Turoctocog Alfa) in Mexican Haemophilia A Patients (NCT03179748) | Novo Nordisk A/S | 2018-06-20 |
| A Research Study Looking at How a Factor VIII Medicine Called Turoctocog Alfa Pegol (N8-GP) Works in People With Haemophilia A (NCT03528551) | Novo Nordisk A/S | 2018-04-30 |
| Research Study to Look at Side Effects During Regular Injection With Factor VIII Medicine Named Turoctocog Alfa for a 8 Weeks Period (NCT03449342) | Novo Nordisk A/S | 2018-03-01 |
| A Trial Evaluating the Efficacy and Safety of Prophylactic Administration of Concizumab in Haemophilia A and B Patients With Inhibitors (NCT03196284) | Novo Nordisk A/S | 2017-08-10 |
| A Trial Comparing Nonacog Beta Pegol (N9-GP) and ALPROLIX® in Patients With Haemophilia B (NCT03075670) | Novo Nordisk A/S | 2017-03-07 |
| Safety, Tolerability, and Pharmacokinetics Study of Turoctocog Alfa Pegol Injected Under the Skin in Patients With Haemophilia A (NCT02994407) | Novo Nordisk A/S | 2017-01-30 |
| Efficacy and Safety of Turoctocog Alfa for Prophylaxis and Treatment of Bleeding Episodes in Previously Treated Chinese Patients With Haemophilia A (NCT02938585) | Novo Nordisk A/S | 2016-12-12 |
| A Multi-centre, Comparative, Double Blind, Randomised Cross-over Trial Investigating Single Dose Pharmacokinetics and Safety of Turoctocog Alfa Pegol From the Pivotal Process and Turoctocog Alfa Pegol From the Commercial Process in Patients With Severe Haemophilia A (NCT02920398) | Novo Nordisk A/S | 2016-10-04 |
| A Study of Safety and Effectiveness of NovoThirteen® (rFXIII) During Treatment of Congenital FXIII Deficiency in Japan (NCT02670213) | Novo Nordisk A/S | 2016-03-16 |
| Bridging Hemophilia B Experiences, Results and Opportunities Into Solutions (B-HERO-S) (NCT02568202) | Novo Nordisk A/S | 2015-09-01 |
| Pharmacogenetic Testing of Saliva Samples From Patients With Five or More Exposure Days to rFVIIa Analogue in the Adept™2 Trial (NCT02541942) | Novo Nordisk A/S | 2015-04-03 |
| To Quantify the Range of Main Psychosocial Factors Affecting Patients and Caregivers in Their Daily Lives (NCT02241694) | Novo Nordisk A/S | 2014-11-01 |
| A Study to Evaluate Safety and Efficacy of NovoSeven® in Patients With Glanzmann's Thrombasthenia in Japan (NCT01876745) | Novo Nordisk A/S | 2014-10-07 |
| To Investigate Safety and Efficacy of NovoEight® (rFVIII) During Long-term Treatment of Haemophilia A in Japan (NCT02207218) | Novo Nordisk A/S | 2014-08-04 |
| Safety and Efficacy of Turoctocog Alfa Pegol (N8-GP) in Previously Untreated Patients With Haemophilia A (NCT02137850) | Novo Nordisk A/S | 2014-06-26 |
| Safety and Efficacy of Turoctocog Alfa During Long-Term Treatment of Severe and Moderately Severe Haemophilia A (NCT02035384) | Novo Nordisk A/S | 2014-06-05 |
| Project to Update the Study of Congenital Haemophilia in Spain (NCT01959555) | Novo Nordisk A/S | 2014-03-01 |
| Investigating the Bioequivalence of Eptacog Alfa A 6 mg and NovoSeven® in Healthy Male Subjects (NCT02084810) | Novo Nordisk A/S | 2014-03-01 |
| Impact of Pain on Functional Impairment and Quality of Life in Adults With Hemophilia (NCT01988532) | Novo Nordisk A/S | 2013-10-01 |
| A Trial Investigating the Pharmacokinetics and Pharmacodynamics of rFVIIa in Patients With Haemophilia A or B With or Without Inhibitors (NCT01949792) | Novo Nordisk A/S | 2013-09-01 |
| A Multinational, Open-Label, Non-Controlled Trial on Safety, Efficacy and Pharmacokinetics of NNC 0129-0000-1003 in Previously Treated Paediatric Patients With Severe Haemophilia A (NCT01731600) | Novo Nordisk A/S | 2013-02-20 |
| Investigation of the Pharmacokinetics of Turoctocog Alfa in Subjects With Haemophilia A (NCT01692925) | Novo Nordisk A/S | 2012-12-01 |
| Safety and Efficacy of Turoctocog Alfa in Prevention and Treatment of Bleeds in Previously Untreated Children With Haemophilia A (NCT01493778) | Novo Nordisk A/S | 2012-09-17 |
| Evaluating the Haemostatic Effect of NNC 0129-0000-1003 During Surgical Procedures in Subjects With Haemophilia A. (NCT01489111) | Novo Nordisk A/S | 2012-08-03 |
| A Multi-centre, Open Labelled, Multiple Dosing Trial Investigating Safety, Pharmacokinetics and Pharmacodynamics of NNC 0172-2021 Administered Subcutaneously to Healthy Male Subjects and Haemophilia Subjects (NCT01631942) | Novo Nordisk A/S | 2012-06-26 |
| Safety, Efficacy and Pharmacokinetics of NNC-0156-0000-0009 in Previously Treated Children With Haemophilia B. (NCT01467427) | Novo Nordisk A/S | 2012-05-16 |
| Investigation of the Pharmacokinetics of NNC172-2021, at Two Different Dose Levels, in Healthy Japanese Subjects (NCT01555749) | Novo Nordisk A/S | 2012-03-12 |
| Evaluation of Safety and Efficacy, Including Pharmacokinetics, of NNC 0129-0000-1003 When Administered for Treatment and Prophylaxis of Bleeding in Subjects With Haemophilia A (NCT01480180) | Novo Nordisk A/S | 2012-01-30 |
| Epidemiological Study on Haemophilia Care and Orthopaedic Status in Developing Countries (NCT01503567) | Novo Nordisk A/S | 2012-01-01 |
| Efficacy and Safety of NNC 0078-0000-0007 in Patients With Congenital Haemophilia and Inhibitors (NCT01392547) | Novo Nordisk A/S | 2011-07-01 |
| Survey Evaluating the Psychosocial Effects of Living With Haemophilia (NCT01322620) | Novo Nordisk A/S | 2011-06-03 |
| A Single Dose Trial of NNC 0155-0000-0004 in Patients With Haemophilia A (NCT01365520) | Novo Nordisk A/S | 2011-06-01 |
| A Long-term Assessment of Physical Activity, Range of Motion, and Functional Status Following Elective Orthopedic Surgery in Hemophilia Patients With Inhibitors (NCT01830712) | Novo Nordisk A/S | 2011-04-01 |
| Observational Study on Safety and Efficacy of NovoSeven® in Subjects With Congenital FVII Deficiency (NCT01312636) | Novo Nordisk A/S | 2011-03-01 |
| Investigating Safety and Pharmacokinetics of NNC 0128-0000-2011 Compared to NNC 0128-0000-2021 in Healthy Male Subjects (NCT01272206) | Novo Nordisk A/S | 2011-01-01 |
| Investigating Safety and Pharmacokinetics of 2 Different Single Doses of NNC128-0000-2011 in Haemophilia A or B Patients (NCT01288391) | Novo Nordisk A/S | 2011-01-01 |
| Safety and Efficacy of Monthly Replacement Therapy With Recombinant Factor XIII (rFXIII) in Paediatric Subjects With Congenital Factor XIII A-subunit Deficiency (NCT01253811) | Novo Nordisk A/S | 2011-01-01 |
| A Single Dose Trial of Recombinant Factor VIII (N8) in Japanese Subjects With Haemophilia A: An Extension to Trial NN7008-3543 (NCT01238367) | Novo Nordisk A/S | 2010-11-01 |
| Safety of a Single Intravenous Dose of Recombinant Factor XIII in Children With Congenital FXIII A-subunit Deficiency (NCT01230021) | Novo Nordisk A/S | 2010-11-01 |
| Observational Study on Safety of Room Temperature Stable NovoSeven® in Patients With Haemophilia A or B (NCT01220141) | Novo Nordisk A/S | 2010-11-01 |
| Safety of NNC 0172-0000-2021 in Healthy Male Subjects and Subjects With Haemophilia A or B (NCT01228669) | Novo Nordisk A/S | 2010-10-25 |
| Observational Study Describing the Usual Clinical Practice Use of NovoSeven® in the Home Treatment of Joint Bleeds in Patients With Haemophilia A or B and Inhibitors (NCT01234545) | Novo Nordisk A/S | 2010-10-01 |
| Safety and Pharmacokinetics of NNC 0129-0000-1003 in Subjects With Haemophilia A (NCT01205724) | Novo Nordisk A/S | 2010-09-01 |
| Safety and Efficacy of Turoctocog Alfa in Previously Treated Male Children With Haemophilia A (NCT01138501) | Novo Nordisk A/S | 2010-06-01 |
| Safety and Efficacy of Turoctocog Alfa (N8) in Prevention and On-demand Treatment of Bleeding Episodes in Subjects With Haemophilia A: An Extension to Trials NN7008-3543, NN7008-3545, NN7008-3600, NN7008-3893 and NN7008-4015 (NCT00984126) | Novo Nordisk A/S | 2009-10-26 |
| Safety of Monthly Recombinant Factor XIII Replacement Therapy in Subjects With Congenital Factor XIII Deficiency: An Extension to Trial F13CD-1725 (NCT00978380) | Novo Nordisk A/S | 2009-09-21 |
| Safety of 40K Pegylated Recombinant Factor IX in Non-Bleeding Patients With Haemophilia B (NCT00956345) | Novo Nordisk A/S | 2009-08-01 |
| A Single Dose Trial Investigating Safety and Local Tolerability of Ascending Doses of Long Acting Activated Recombinant Human Factor VII in Healthy Male Volunteers (NCT00951873) | Novo Nordisk A/S | 2009-07-01 |
| Safety and Mode of Action of a Single Dose and Multiple Doses of Long Acting Activated Recombinant Human Factor VII in Patients With Haemophilia A and B (NCT00922792) | Novo Nordisk A/S | 2009-06-01 |
| PROPACT: Retrospective Prophylaxis Patient Case Collection (NCT00882778) | Novo Nordisk A/S | 2009-04-01 |
| Safety and Efficacy of Turoctocog Alfa in Haemophilia A Subjects (NCT00840086) | Novo Nordisk A/S | 2009-04-01 |
| Comparison of the Action of Drugs in the Body and Safety of N8 and Advate® in Haemophilia A Subjects (NCT00837356) | Novo Nordisk A/S | 2009-03-01 |
| Safety, Tolerability and Pharmacokinetics of NN1731 in Healthy Volunteers (NCT00822185) | Novo Nordisk A/S | 2009-01-01 |
| Evaluation of Recombinant Factor XIII for Prevention of Bleeding in Patients With FXIII Inherited Deficiency (NCT00713648) | Novo Nordisk A/S | 2008-08-01 |
| Observational Study on the Efficacy and Safety of NovoSeven® During "Real-life" Usage in Germany (NCT00697320) | Novo Nordisk A/S | 2008-06-01 |
| Observational Registry of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (NCT00703911) | Novo Nordisk A/S | 2008-03-01 |
| Post-marketing Safety Surveillance of NovoSeven® in Patients With Haemophilia and Inhibitors by Means of the UK Haemophilia Database (NCT00853086) | Novo Nordisk A/S | 2008-01-01 |
| Bioequivalence of NovoSeven® and a NovoSeven® Formulation Stable at Room Temperature in Healthy Male Subjects (NCT01561417) | Novo Nordisk A/S | 2006-04-01 |
| Prediction of the Efficacy of Activated Recombinant Human Factor VII in Adult Congenital Haemophilia A or B Patients With Inhibitors by Use of Thromboelastography (NCT01561924) | Novo Nordisk A/S | 2005-11-01 |
| Intra-subject Variability Following Administrations of Activated Recombinant Human Factor VII in Haemophilia Patients in a Non-bleeding State (NCT01562457) | Novo Nordisk A/S | 2005-11-01 |
| Treatment of Congenital Factor VII Deficiency (NCT01779921) | Novo Nordisk A/S | 2005-10-01 |
| Dose Response to Recombinant Factor VIIa When Administered for Bleed (NCT00104455) | Novo Nordisk A/S | 2004-06-01 |
| Efficacy of NovoSeven® in Bleeding Prophylaxis in Hemophilia (NCT00108758) | Novo Nordisk A/S | 2004-03-01 |
| Observational Registry of the Treatment of Glanzmann's Thrombasthenia (NCT01476423) | Novo Nordisk A/S | 2004-01-01 |
| Safety and Pharmacokinetics of Recombinant Factor XIII Administration in Healthy Volunteers (NCT01848002) | Novo Nordisk A/S | 2003-05-01 |
| Safety and Pharmacokinetics of Recombinant Factor XIII in Patients With Congenital Factor Xlll Deficiency (NCT00056589) | Novo Nordisk A/S | 2003-03-01 |
| Safety and Pharmacokinetics of Recombinant Factor XIII in Healthy Volunteers (NCT01847989) | Novo Nordisk A/S | 2003-01-01 |
| High Dose of Activated Recombinant Human Factor VII for Treatment of Mild/Moderate Joint Bleeds in Haemophilia Patients With Inhibitors (NCT00571584) | Novo Nordisk A/S | 2002-11-01 |
| Pharmacokinetics of Single Bolus Dose of NovoSeven® in Paediatric and Adult Patients With Haemophilia A or B in a Non- Bleeding State (NCT01562587) | Novo Nordisk A/S | 2002-09-01 |
| Safety and Tolerability of Intravenous Doses of Activated Recombinant Human Factor VII in Healthy Volunteers (NCT01563471) | Novo Nordisk A/S | 2001-10-01 |
| Trial of NovoSeven® in Haemophilia - Joint Bleeds (NCT00108797) | Novo Nordisk A/S | 2001-09-01 |
| Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors Under Normal Clinical Practice (NCT01579955) | Novo Nordisk A/S | 1999-03-10 |
| Non-Interventional Study of NovoSeven® Used as On-demand Treatment of Bleeds in Patients With Haemophilia A and B With Inhibitors (NCT01586936) | Novo Nordisk A/S | 1999-03-10 |
| Non-Interventional Study of NovoSeven® Used in Patients With Haemophilia A and B With Inhibitors When Undergoing Surgery (NCT01579968) | Novo Nordisk A/S | 1999-03-10 |
| Safety and Efficacy of Activated Recombinant Human Factor VII in Haemophilia Patients With Inhibitors During and After Major Surgery (NCT01561391) | Novo Nordisk A/S | 1998-04-01 |